Abstract. The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia. Eight patients with tumor-associated hypercalcemia received intravenous infusion of pamidronate (45 mg) and their high mean serum calcium concentration significantly decreased from 3.56 mmol /L_, to 2.62 mmol/L 7 days after treatment. Serum intact PTH before treatment had been suppressed to below normal in all patients but returned to normal range in six patients within 7 days after treatment. Urinary PTH related peptide (PTHrP) excretion before treatment had been elevated in seven patients and then significantly increased further after pamidronate therapy. The serum bone Gla protein concentration was not apparently changed by the treatment. Pamidronate in serum was rapidly eliminated after the treatment and urinary excretion reached a plateau on the second day (13.8% of the administered dose), suggesting that the major portion of the infused dose had been distributed to the bone and other tissues. These findings suggest that pamidronate has a potent hypocalcemic effect and that PTHrP production in malignant tumors could be affected by pamidronate therapy.
PAMIDRONATE (disodium 3-amino-1-hydroxypropylidene-1,1-bisphosphonate pentahydrate), a second generation bisphosphonate, has been used in the treatment of patients with tumor-associated hypercalcemia, and reduction in serum calcium in response to this drug has been reported [1] [2] [3] . It has generally been accepted that pamidronate reduces serum calcium through the suppression of osteoclast activity. Hypercalcemia in patients with malignancies almost always results from increased bone resorption and is often caused by humoral factors.
Parathyroid hormone-related peptide (PTHrP) is considered to be a major factor involved in tumor-associated hypercalcemia [4, 5] . Recently, the measurement of PTHrP in urine has been reported to be a sensitive and useful method for evaluating PTHrP production in various states of a disease [6] . Although several biochemical responses to pamidronate therapy in the treatment of various bone disorders have been reported 11, 7- 101, the precise effect of this drug on biochemical and endocrinological changes in tumor-associated hypercalcemic patients
has not yet been completely clarified.
In the present study, we investigated the effect of pamidronate therapy on the PTHrP concentration in urine as well as on other endocrinological and biochemical responses in eight patients with tumor-associated hypercalcemia. We also measured the pamidronate concentrations in serum and urine to examine its pharmacokinetics.
Subjects and Methods
Eight patients with tumor-associated hypercalcemia (Table 1) received a single intravenous infusion of 45 mg of pamidronate dissolved in 500 ml of normal saline over 4 h. This infusion had been preceded by hydration therapy of more than 2000 ml /day of normal saline for at least 2 days. Serum electrolytes, intact PTH and bone Gla protein (BGP), which is also called osteocalcin, were measured on days 0, 2, 4 and 7. Urine electrolytes, PTHrP and hydroxyproline were measured on days -1, 0, 1, 2, 3, 4, and 7 in fasting morning urine samples.
Intact PTH (1-84) was measured by Allegro immunoradiometric assay (Nichols). PTHrP was measured by radioimmunoassay with an antibody directed against the C-terminal fragments of PTHrP [11, 12] . Anti-C- had been high. In these patients, PTHrP might have played crucial role in the manifestation of hypercalcemia.
Interestingly, pamidronate therapy increased intact PTH as well as the urinary excretion of PTHrP without much change in renal function.
It is known that PTH is physiologically regulated by serum calcium levels and the progressive increase in PTH after treatment could be caused by this control mechanism.
On the other hand, the release of PTHrP has been reported to be independent of the serum calcium concentration in hypercalcemic patients with several malignant tumors [10, 16] . There is some evidence that PTHrP plays roles in calcium metabolism such as that of a regulatory factor in maintaining physiological hypercalcemia in the fetus [17, 18] . PTHrP is reported to exist in human milk and PTHrP mRNA is expressed in the normal lactating mammary tissue, suggesting that it may act as a hormone for the mobilization of calcium from the bone or for transferring calcium to the milk [19, 20] . These findings indicate the possibility that PTHrP has limited but physiological actions even in normal humans including the fetus. Although the precise regulatory mechanism of PTHrP release in both physiological and pathological conditions is not clear, it is reported that an increase in calcium in the medium inhibits PTHrP release from cultured cytotrophoblast cells [21] . Moreover, low- ering the extracellular calcium concentration resulted in an increase in PTHrP production in cultured human squamous carcinoma cells [22] . These findings seem to shed some light on our present results. In contrast to our observation of a progressive increase in urinary PTHrP after pamidronate therapy, a few reports showed that pamidronate did not affect the plasma PTHrP concentration in patients with tumor-associated hypercalcemia [1, 10] . Although the reason for this discordance is unclear, the following possibility has been considered. PTHrP is reported to exist at least as two molecular forms in the plasma of patients with tumor-associated hypercalcemia:
one is an N-terminal peptide and the other is a C-terminal peptide [16, 23] . C-terminal fragments of PTHrP metabolized from intact PTHrP are readily excreted into urine and PTHrP excretion in urine is much higher than that in plasma [6] , suggesting that urinary PTHrP might be a sensitive index for the evaluation of PTHrP synthesis.
The measurement of PTHrP levels in the urine may therefore be a more sensitive way of evaluating such a small change as seen in the present investigation than the measurement of the PTHrP concentration in the plasma. Body et al. reported not significant but slight increase in plasma PTHrP after pamidronate therapy in some patients with tumor-associated hypercalcemia [10] , suggesting that further investigations with the measurement of urinary PTHrP will be required to clarify the precise effect of pamidronate.
An increase in serum alkaline phosphatase activity may be consistent with the increase in PTH and/or PTH-like activity. The effects of pamidronate on bone metabolism were also evaluated by measuring urinary excretion of hydroxyproline and serum BGP. Because urinary hydroxyproline could be used as a marker for bone resorption, a significant decrease in urinary excretion of hydroxyproline by pamidronate therapy confirms that bone resorption caused by PTHrP was strongly suppressed by this drug. In contrast to the increase in serum alkaline phosphatase activity, serum BGP did not show a significant change following the use of this drug. It is possible that serum BGP might not reflect osteoblastic activity which is linked to acute suppression of the function of osteoclasts within such a short term.
When 14C-labeled pamidronate was administered to rats and mice, pamidronate was mainly distributed in bone [24] and the elimination half-life of pamidronate from bone was estimated to be approximately 300 days [25] . Furthermore pamidronate was mainly excreted in urine, in which its metabolites were not detected [25] . In the present study, we demonstrated that pamidronate in serum was rapidly eliminated after administration. Urinary excretion of pamidronate almost reached a plateau on the second day and total urinary excretion was approximately 14% of the dose administered. Most of the infused dose may therefore be distributed to the bone and other tissues in patients with tumor-associated hypercalcemia. The amount of pamidronate retained by the body, which was estimated in terms of its excretion into urine, was apparently high compared with a previous report dealing with normocalcemic patients with bone metastases [26] . It is unclear why the retention estimates for the hypercalcemic patients in our study were greater than those for normocalcemic patients with bone metastases.
However, this fact would still indicate the suitability of pamidronate treatment for patients with tumor-associated hypercalcemia.
In conclusion, pamidronate is an effective and potent drug for tumor-associated hypercalcemia. Increases in urinary PTHrP excretion along with a rapid reverse decrease in serum calcium following pamidronate treatment suggested that PTHrP secretion from a tumor could be partially regulated by the serum calcium concentration.
